5 Revealing Analyst Questions From Chemed's Q3 Earnings Call

Chemed’s third quarter was marked by continued operational challenges in both the VITAS and Roto-Rooter businesses, resulting in a negative market reaction. Management attributed the margin compression to higher costs associated with increased hospital-based admissions at VITAS and a shift toward paid leads in Roto-Rooter, which elevated expenses and weighed on profitability. CEO Kevin McNamara pointed to stabilization in VITAS’s Medicare Cap exposure and highlighted a “high watermark” in hospital admission ratios, while also noting that Roto-Rooter’s residential plumbing campaign yielded encouraging results. CFO Michael Witzeman described the quarter’s gross margin as “exactly in line with our guidance,” but acknowledged that segment margins remain below long-term targets.

Is now the time to buy CHE? Find out in our full research report (it’s free for active Edge members).

While we enjoy listening to the management's commentary, our favorite part of earnings calls are the analyst questions. Those are unscripted and can often highlight topics that management teams would rather avoid or topics where the answer is complicated. Here is what has caught our attention.

Our Top 5 Analyst Questions From Chemed’s Q3 Earnings Call

• Benjamin Hendrix (RBC Capital Markets) asked how management expects to bridge Q3 results to full-year guidance, especially with both segments tracking below Street estimates. CFO Michael Witzeman cited Q4 seasonality and anticipated margin improvements as the primary drivers.
• Brian Tanquilut (Jefferies) questioned the sustainability of margin improvements, particularly in Roto-Rooter, and how higher marketing costs affect long-term business models. Witzeman explained that operational initiatives and lead generation should offset margin pressure over time.
• Joanna Gajuk (Bank of America) inquired about Roto-Rooter’s margin outlook, given the shift to paid leads and recent margin trends. Witzeman stated that while near-term pressures remain, management expects margins to trend back toward 25–26% with improved operational controls.
• Joanna Gajuk (Bank of America) also asked about Medicare Cap risk in Florida and how patient mix adjustments are reducing that risk. VITAS CEO Joel Wherley said ongoing monitoring of hospital admissions and length of stay is central to avoiding future liabilities.
• Joanna Gajuk (Bank of America) followed up on the drivers behind sequential improvements in VITAS’s gross margin. Witzeman attributed this to targeted efficiencies and cost management at the program level.

Catalysts in Upcoming Quarters

Looking ahead, our analysts will be monitoring (1) whether VITAS can sustain its hospital admission ratio and avoid Medicare Cap limitations in Florida, (2) margin recovery progress at Roto-Rooter amid higher marketing spend, and (3) the ramp-up of new program launches, such as the Pinellas County location. Developments in lead generation effectiveness and operational improvements will also be key indicators of business momentum.

Chemed currently trades at $440.68, in line with $439.05 just before the earnings. At this price, is it a buy or sell? The answer lies in our full research report (it’s free for active Edge members).

High-Quality Stocks for All Market Conditions

Trump’s April 2025 tariff bombshell triggered a massive market selloff, but stocks have since staged an impressive recovery, leaving those who panic sold on the sidelines.

Take advantage of the rebound by checking out our Top 9 Market-Beating Stocks. This is a curated list of our High Quality stocks that have generated a market-beating return of 183% over the last five years (as of March 31st 2025).

Stocks that made our list in 2020 include now familiar names such as Nvidia (+1,545% between March 2020 and March 2025) as well as under-the-radar businesses like the once-micro-cap company Tecnoglass (+1,754% five-year return). Find your next big winner with StockStory today.

StockStory is growing and hiring equity analyst and marketing roles. Are you a 0 to 1 builder passionate about the markets and AI? See the open roles here.